Drug · CHEMBL50
QUERCETIN
7 sourcespipelines-2026-09-18-0.3.1
Cite this record
ConductScience Library. QUERCETIN. Drugs and targets, record CHEMBL50. Release pipelines-2026-09-18-0.3.1, 18 Sept 2026. https://conductscience.org/library/drugs/CHEMBL50
On this page
Drug
Names and IDs as ChEMBL gives them, through Open Targets.
- Other names
3'-hydroxykaempferol, C.i. 75670, C.i. natural red 1, Ci-75670, Corvitin, Cyanidenolon 1522, Korvitin, LDN 0052529, LDN-0052529, Lipoflavon, Meletin, NSC 57655, NSC 9219, NSC-57655, NSC-9219, Quercetin (constituent of ginkgo), Quercetine, Quercetol, Quertin, Quertine, Sophoretin, Xanthaurine
- ChEMBL
Targets0
The targets ChEMBL's mechanism records give for the drug, through Open Targets. A mechanism record says what the drug acts on, not how strongly.
None in this release.
Diseases39
The diseases Open Targets' clinical reports study the drug for, the most trial reports first. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
1 to 10 of 39Source Open Targets
See all 39 diseasesTrials62
Trials whose record names the drug by a name ChEMBL states, posted results first, then the largest. Open Targets read each trial's text to find its drugs. 1 more rests on that reading alone and is shown because the trial's posted result groups or NLM's indexing of its papers name the drug. 2 more that Open Targets linked to it are not shown, since the release's checks do not confirm them.
| Trial | Title | Phase | Participants | Results first posted | Named as | Linked by | Source |
|---|---|---|---|---|---|---|---|
| NCT02463357 | Three New Ideas to Protect Special Forces From the Stress of High Altitude | Phase 4 | 148 | 2021-03-30 | quercetin | Its name | ClinicalTrials.gov |
| NCT04313634 | Targeting Cellular Senescence With Senolytics to Improve Skeletal Health in Older Humans | Phase 2 | 74 | 2024-07-22 | quercetin | Its name | ClinicalTrials.gov |
| NCT01722669 | Quercetin PK/PD Study in Healthy Adults and Patients With Hypercoagulable States | Early phase 1 | 38 | 2020-10-12 | quercetin | Its name | ClinicalTrials.gov |
| NCT05422885 | Safety and Feasibility of Dasatinib and Quercetin in Adults at Risk for Alzheimer's Disease | Phase 1/2 | 15 | 2025-03-17 | quercetin | Its name | ClinicalTrials.gov |
| NCT04252625 | Trial of Quercetin, Bromelain, Rye Flower Pollen & Papain on Reducing Severity of Radiation-Induced Prostatitis | Phase 2 | 10 | 2025-05-06 | quercetin | Its name | ClinicalTrials.gov |
| NCT01708278 | Beneficial Effects of Quercetin in Chronic Obstructive Pulmonary Disease (COPD) | Phase 1 | 9 | 2016-12-26 | quercetin | Its name | ClinicalTrials.gov |
| NCT04063124 | Senolytic Therapy to Modulate Progression of Alzheimer's Disease | Phase 1/2 | 5 | 2023-03-06 | quercetin | Its name | ClinicalTrials.gov |
| NCT05456022 | Therapeutic Efficacy of Quercetin Versus Its Encapsulated Nanoparticle on Tongue Squamous Cell Carcinoma Cell Line | Phase 2 | 1,000,000 | quercetin | Its name | ClinicalTrials.gov | |
| NCT06861088 | The Effect of Kinisoquin™ on Thromboembolic Events in Patients With Metastatic or Locally Advanced Pancreatic Cancer | Phase 3 | 480 | quercetin | Its name | ClinicalTrials.gov | |
| NCT04853199 | Quercetin In The Treatment Of SARS-COV 2 | Early phase 1 | 200 | quercetin | Its name | ClinicalTrials.gov |
1 to 10 of 62
See all 62 trialsComparisons in its trials2
Comparisons Trial comparisons calculated in the trials whose record names the drug, most participants first. A comparison in one of its trials does not always compare the drug, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Arm 1: Q-Urol vs Arm 2: Placebo: deaths from any cause | 0 of 5 | 0 of 5 | 10 | NCT04252625 | Trial comparisons |
| Arm 1: Q-Urol vs Arm 2: Placebo: serious adverse events | 0 of 5 | 0 of 5 | 10 | NCT04252625 | Trial comparisons |
Papers from its trials32
The papers the trials whose record names the drug list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Tests in its trials2
The tests ConductCognition runs that the trials whose record names the drug name in their registered outcomes, as ScienceGraph matched them. ConductCognition's list names the tests it runs, not every test a trial used.
| Test | Trials naming it as an outcome | As a primary outcome | Source |
|---|---|---|---|
| 1-Back Task | 1 | 1 | ConductCognition |
| 2-Back Task | 1 | 1 | ConductCognition |
Data dates
The date of each source this release read.
Sources 7
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ConductCognition's list of its testsOur own data
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ConductCognition's list of its testsOur own data: ConductCognition's list of its tests, https://conductcognition.com
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this drug from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/drugs/v1/CHEMBL50
GET https://conductscience.org/api/drugs/v1/CHEMBL50/diseases?page=2